Cancer predisposition syndromes

Cancer Treatment and Research

Volumn 150, Issue , 2009, Pages 223-238

  Weinstein, Joanna L ^a   Ayyanar, Kanyalakshmi ^b   Watral, Melody A ^c  

^a CHILDREN'S MEMORIAL HOSPITAL   (United States)

^b KOSAIR CHILDREN'S HOSPITAL   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BRAIN TUMOR; CHEMICALLY INDUCED DISORDER; CHILD; DRUG CONTRAINDICATION; FAMILIAL CANCER; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; MALE; RADIATION INDUCED NEOPLASM; RADIOTHERAPY; REVIEW; SECOND CANCER; TUMOR GENE;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHILD; FEMALE; GENES, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; NEOPLASTIC SYNDROMES, HEREDITARY; RADIOTHERAPY;

EID: 77956625965     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/b109924_15     Document Type: Article

References (144)

1. Wong FL, Boice JD, Jr., Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA. 1997;278:1262-1267. (Pubitemid 27435614)
2. Knudson AG, Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971;68:820-823.
3. Moll AC, Imhof SM, Bouter LM, et al. Second primary tumors in patients with hereditary retinoblastoma: a register-based follow-up study, 1945-1994. Int J Cancer. 1996;67:515-519. (Pubitemid 26274108)
4. Meadows AT. Retinoblastoma survivors: sarcomas and surveillance. J Natl Cancer Inst. 2007;99:3-5.
5. Sagerman RH, Cassady JR, Tretter P, et al. Radiation induced neoplasia following external beam therapy for children with retinoblastoma. Am J Roentgenol Radium Ther Nucl Med. 1969;105:529-535.
6. Varley JM, Evans DG, Birch JM. Li-Fraumeni syndrome - a molecular and clinical review. Br J Cancer. 1997;76:1-14. (Pubitemid 27250068)
7. Varley JM,McGownG, ThorncroftM, et al. Germ-linemutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res. 1997;57:3245-3252. (Pubitemid 27351742)
8. Hottinger AF, Khakoo Y. Update on the management of familial central nervous system tumor syndromes. Curr Neurol Neurosci Rep. 2007;7:200-207. (Pubitemid 46831513)
9. Mastrangelo D, De Francesco S, Di Leonardo A, et al. Does the evidence matter in medicine? The retinoblastoma paradigm. Int J Cancer. 2007;121:2501-2505. (Pubitemid 350022420)
10. Broniscer A, Ke W, Fuller CE, et al. Second neoplasms in pediatric patients with primary central nervous system tumors: the St. Jude Children's Research Hospital experience. Cancer. 2004;100:2246-2252. (Pubitemid 38580347)
11. Stavrou T, BromleyCM,NicholsonHS, et al. Prognostic factors and secondarymalignancies in childhood medulloblastoma. J Pediatr Hematol Oncol. 2001;23:431-436. (Pubitemid 33031771)
12. Narod SA, Stiller C, Lenoir GM. An estimate of the heritable fraction of childhood cancer. Br J Cancer. 1991;63:993-999.
13. Kingston JE, Hawkins MM, Draper GJ, et al. Patterns of multiple primary tumours in patients treated for cancer during childhood. Br J Cancer. 1987;56:331-338. (Pubitemid 17161768)
14. Meadows AT, Baum E, Fossati-Bellani F, et al. Second malignant neoplasms in children: an update from the Late Effects Study Group. J Clin Oncol. 1985;3:532-538. (Pubitemid 15111401)
15. Little MP, de Vathaire F, Shamsaldin A, et al. Risks of brain tumour following treatment for cancer in childhood: modification by genetic factors, radiotherapy and chemotherapy. Int J Cancer. 1998;78:269-275. (Pubitemid 28445359)
16. Garwicz S, Anderson H, Olsen JH, et al. Second malignant neoplasms after cancer in childhood and adolescence: a population-based case-control study in the 5 Nordic countries. The Nordic Society for Pediatric Hematology and Oncology. The Association of the Nordic Cancer Registries. Int J Cancer. 2000;88:672-678.
17. Field M, Shanley S, Kirk J. Inherited cancer susceptibility syndromes in paediatric practice. J Paediatr Child Health. 2007;43:219-229. (Pubitemid 46570079)
18. Clayton EW. Ethical, legal, and social implications of genomic medicine. N Engl J Med. 2003;349:562-569. (Pubitemid 36951369)
19. Eng CM, Schechter C, Robinowitz J, et al. Prenatal genetic carrier testing using triple disease screening. JAMA. 1997;278:1268-1272.
20. WilfondBS, Fost N.The cystic fibrosis gene: medical and social implications for heterozygote detection. JAMA. 1990;263:2777-2783. (Pubitemid 20181572)
21. Pyeritz RE. Family history and genetic risk factors: forward to the future. JAMA. 1997;278:1284-1285. (Pubitemid 27435619)
22. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol. 1996;14:1730-1736; discussion 7-40.
23. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol. 2003;21:2397-2406.
24. Ferner RE. Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Lancet Neurol. 2007;6:340-351. (Pubitemid 46367948)
25. Korf BR. Malignancy in neurofibromatosis type 1. Oncologist. 2000;5:477-485.
26. Rasmussen SA, Friedman JM. NF1 gene and neurofibromatosis 1. Am J Epidemiol. 2000;151:33-40. (Pubitemid 30470392)
27. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arc Neurol. 1988;45:575-578.
28. Wu BL, Austin MA, Schneider GH, et al. Deletion of the entire NF1 gene detected by the FISH: four deletion patients associated with severe manifestations. Am J Med Genet. 1995;59:528-535.
29. Leppig KA, Kaplan P, Viskochil D, et al. Familial neurofibromatosis 1 microdeletions: cosegregation with distinct facial phenotype and early onset of cutaneous neurofibromata. Am J Med Genet. 1997;73:197-204.7 (Pubitemid 27514732)
30. Carey JC, Laub JM, Hall BD. Penetrance and variability in neurofibromatosis: a genetic study of 60 families. Birth Defects Original Article Series. 1979;15:271-281. (Pubitemid 10183921)
31. Friedman JM, Birch PH. Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients. Am J Med Genet. 1997;70:138-143. (Pubitemid 27184570)
32. National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13-15, 1987. Neurofibromatosis. 1988;1:172-178.
33. Griffiths S, Thompson P, Frayling I, et al. Molecular diagnosis of neurofibromatosis type 1: 2 years experience. Familial Cancer. 2007;6:21-34. (Pubitemid 46295293)
34. Upadhyaya M, Osborn MJ, Maynard J, et al. Mutational and functional analysis of the neurofibromatosis type 1 (NF1) gene. Human Genet. 1997;99:88-92. (Pubitemid 26419862)
35. Fahsold R, Hoffmeyer S, Mischung C, et al. Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain. Am J Human Genet. 2000;66:790-818. (Pubitemid 30470484)
36. Listernick R, Louis DN, Packer RJ, et al. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 optic pathway glioma task force. Ann Neurol. 1997;41:143-149. (Pubitemid 27082094)
37. Listernick R, Charrow J, Greenwald M, et al. Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr. 1994;125:63-66. (Pubitemid 24225179)
38. Listernick R, Darling C, Greenwald M, et al. Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history. J Pediatr. 1995;127:718-722.
39. Gutmann DH, AylsworthA,Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 1997;278:51-57. (Pubitemid 27274517)
40. Pollack IF, Shultz B, Mulvihill JJ. The management of brainstem gliomas in patients with neurofibromatosis 1. Neurology. 1996;46:1652-1660. (Pubitemid 26185788)
41. BaserME,DGRE,GutmannDH.Neurofibromatosis 2. Curr OpinNeurol. 2003;16:27-33. (Pubitemid 36206759)
42. Singhal S, Birch JM, Kerr B, et al. Neurofibromatosis type 1 and sporadic optic gliomas. Arch Dis Child. 2002;87:65-70. (Pubitemid 34753778)
43. Guillamo JS, Creange A, Kalifa C, et al. Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients. Brain. 2003;126:152-160. (Pubitemid 36068565)
44. Hoyt WF, Baghdassarian SA. Optic glioma of childhood. Natural history and rationale for conservative management. Br J Ophthalmol. 1969;53:793-798.
45. Allen JC. Initial management of children with hypothalamic and thalamic tumors and the modifying role of neurofibromatosis-1. Pediatric Neurosurg. 2000;32:154-162. (Pubitemid 30413204)
46. Brzowski AE, Bazan C, 3rd, Mumma JV, et al. Spontaneous regression of optic glioma in a patient with neurofibromatosis. Neurology. 1992;42:679-681.
47. Perilongo G, Moras P, Carollo C, et al. Spontaneous partial regression of low-grade glioma in children with neurofibromatosis-1: a real possibility. J Child Neurol. 1999;14:352-356. (Pubitemid 29321093)
48. Jamjoom AB, Malabarey T, Jamjoom ZA, et al. Cerebro-vasculopathy and malignancy: catastrophic complications of radiotherapy for optic nerve glioma in a von Recklinghausen neurofibromatosis patient. Neurosurg Rev. 1996;19:47-51. (Pubitemid 26147133)
49. Listernick R, Ferner RE, Liu GT, et al. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol. 2007;61:189-198. (Pubitemid 46557343)
50. Korones DN, Padowski J, Factor BA, et al. Do children with optic pathway tumors have an increased frequency of other central nervous system tumors? Neuro-oncology. 2003;5:116-120. (Pubitemid 36416840)
51. Sharif S, Ferner R, Birch JM, et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol. 2006;24:2570-2575. (Pubitemid 46630636)
52. Shearer P, ParhamD,Kovnar E, et al. Neurofibromatosis type I andmalignancy: review of 32 pediatric cases treated at a single institution. Medical Pediatric Oncol. 1994;22:78-83.
53. Kuenzle C, Weissert M, Roulet E, et al. Follow-up of optic pathway gliomas in children with neurofibromatosis type 1. Neuropediatrics. 1994;25:295-300.
54. McGaughran JM, Harris DI, Donnai D, et al. A clinical study of type 1 neurofibromatosis in northwest England. J Med Genet. 1999;36:197-203. (Pubitemid 29110448)
55. Brodeur GM. The NF1 gene in myelopoiesis and childhood myelodysplastic syndromes. N Engl J Med. 1994;330:637-639. (Pubitemid 24065802)
56. Walther MM, Herring J, Enquist E, et al. von Recklinghausen's disease and pheochromocytomas. J Urol. 1999;162:1582-1586.
57. Evans DG, Baser ME, McGaughran J, et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39:311-314. (Pubitemid 34526349)
58. RuttledgeMH, RouleauGA. Role of the neurofibromatosis type 2 gene in the development of tumors of the nervous system. Neurosurg Focus. 2005;19:E6.
59. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell. 1993;72:791-800. (Pubitemid 23093886)
60. Sufan RI, Jewett MA, Ohh M. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma. Am J Physiol. 2004;287:F1-F6. (Pubitemid 38780576)
61. Stolle C, Glenn G, Zbar B, et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Human Mutation. 1998;12:417-423. (Pubitemid 28512618)
62. Choyke PL, Glenn GM, Walther MM, et al. von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology. 1995;194:629-642.
63. Eisenhofer G, Lenders JW, Linehan WM, et al. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med. 1999;340:1872-1879. (Pubitemid 29272667)
64. Gorlin RJ, Goltz RW. Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. A syndrome. N Engl J Med. 1960;262:908-912.
65. Cawson RA, Kerr GA. The Syndrome of Jaw Cysts, Basal Cell Tumours and Skeletal Abnormalities. Proc Roy Soc Med. 1964;57:799-801.
66. Berlin NI, Van Scott EJ, Clendenning WE, et al. Basal cell nevus syndrome. Combined clinical staff conference at the National Institutes of Health. Ann Int Med. 1966;64:403-421.
67. Gorlin RJ. Nevoid basal cell carcinoma (Gorlin) syndrome. Genet Med. 2004;6:530-539. (Pubitemid 39576548)
68. Evans DG, Ladusans EJ, Rimmer S, et al. Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. JMed Genet. 1993;30:460-464. (Pubitemid 23197262)
69. Gorlin RJ. Nevoid basal cell carcinoma (Gorlin) syndrome: unanswered issues. J Lab Clin Med. 1999;134:551-552.
70. Kimonis VE, Goldstein AM, Pastakia B, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet. 1997;69:299-308. (Pubitemid 27154674)
71. Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Scienc (New York, NY). 1996;272:1668-1671. (Pubitemid 26200029)
72. Gailani MR, Stahle-Backdahl M, Leffell DJ, et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nature Genet. 1996;14:78-81. (Pubitemid 26301550)
73. Gailani MR, Bale AE. Acquired and inherited basal cell carcinomas and the patched gene. Adv Dermatol. 1999;14:261-283; discussion 84.
74. Farndon PA, Del Mastro RG, Evans DG, et al. Location of gene for Gorlin syndrome. Lancet. 1992;339:581-582.
75. Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996;85:841-851. (Pubitemid 26192135)
76. Goodrich LV, Milenkovic L, Higgins KM, et al. Altered neural cell fates and medulloblastoma in mouse patched mutants. Scienc (New York, NY). 1997;277:1109-1113. (Pubitemid 27371635)
77. Raffel C, Jenkins RB, Frederick L, et al. Sporadic medulloblastomas contain PTCH mutations. Cancer Res. 1997;57:842-845. (Pubitemid 27098006)
78. Zurawel RH, Allen C, Chiappa S, et al. Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. Genes, Chromosomes Cancer. 2000;27:44-51.
79. Booth DR. The hedgehog signaling pathway and its role in basal cell carcinoma. Cancer Metastasis Rev. 1999;18:261-284. (Pubitemid 30043862)
80. Cowan R, Hoban P, Kelsey A, et al. The gene for the naevoid basal cell carcinoma syndrome acts as a tumour-suppressor gene in medulloblastoma. Br J Cancer. 1997;76:141-145. (Pubitemid 27279651)
81. Korczak JF, Brahim JS,DiGiovanna JJ, et al.Nevoid basal cell carcinoma syndromewith medulloblastoma in an African-American boy: a rare case illustrating gene-environment interaction. Am J Med Genet. 1997;69:309-314.
82. Walter AW, Pivnick EK, Bale AE, et al. Complications of the nevoid basal cell carcinoma syndrome: a case report. J Pediatr Hematol Oncol. 1997;19:258-262. (Pubitemid 27276296)
83. Nichols KE, Malkin D, Garber JE, et al. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev. 2001;10:83-87. (Pubitemid 32172424)
84. Bottomley RH, Trainer AL, Condit PT. Chromosome studies in a ''cancer family''. Cancer. 1971;28:519-528.
85. Lynch HT, McComb RD, Osborn NK, et al. Predominance of brain tumors in an extended Li-Fraumeni (SBLA) kindred, including a case of Sturge-Weber syndrome. Cancer. 2000;88:433-439. (Pubitemid 30051830)
86. Kleihues P, Schauble B, zur Hausen A, et al. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol. 1997;150:1-13. (Pubitemid 27027090)
87. Chompret A. The Li-Fraumeni syndrome. Biochimie. 2002;84:75-82. (Pubitemid 34477095)
88. Malkin D. p53 and the Li-Fraumeni syndrome. Cancer Genet Cytogenet. 1993;66:83-92. (Pubitemid 23155343)
89. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Scienc (New York, NY). 1990;250:1233-1238. (Pubitemid 120031831)
90. Hisada M, Garber JE, Fung CY, et al. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst. 1998;90:606-611. (Pubitemid 28204804)
91. Srivastava S, Zou ZQ, Pirollo K, et al. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 1990;348:747-749. (Pubitemid 120015153)
92. Frebourg T, Barbier N, Yan YX, et al. Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Human Genet. 1995;56:608-615.
93. Birch JM, Hartley AL, Tricker KJ, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res. 1994;54:1298-1304. (Pubitemid 24108072)
94. Rasheed BK, McLendon RE, Herndon JE, et al. Alterations of the TP53 gene in human gliomas. Cancer Res. 1994;54:1324-1330. (Pubitemid 24108076)
95. PoetaML,Manola J,GoldwasserMA, et al. TP53mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007;357:2552-2561. (Pubitemid 350294222)
96. Nutting C, Camplejohn RS, Gilchrist R, et al. A patient with 17 primary tumours and a germ line mutation in TP53: tumour induction by adjuvant therapy? Clin Onco (Royal College of Radiologists (Great Britain)). 2000;12:300-304.
97. Limacher JM, Frebourg T, Natarajan-Ame S, et al. Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer. 2001;96:238-242. (Pubitemid 33081228)
98. MullinsKJ,RubioA,Myers SP, et al. Malignant ependymomas in a patient with Turcot's syndrome: case report and management guidelines. Surg Neurol. 1998;49:290-294. (Pubitemid 28106874)
99. Costa OL, Silva DM, Colnago FA, et al. Turcot syndrome. Autosomal dominant or recessive transmission? Dis Colon Rectum. 1987;30:391-394. (Pubitemid 17078526)
100. Foulkes WD. A tale of four syndromes: familial adenomatous polyposis, Gardner syndrome, attenuated APC and Turcot syndrome. Qjm. 1995;88:853-863. (Pubitemid 26009653)
101. Mori T, Nagase H, Horii A, et al. Germ-line and somatic mutations of the APC gene in patients with Turcot syndrome and analysis of APC mutations in brain tumors. Genes Chromosomes Cancer. 1994;9:168-172. (Pubitemid 24074733)
102. Hamilton SR, Liu B, Parsons RE, et al. The molecular basis of Turcot's syndrome. N Engl J Med. 1995;332:839-847.
103. De Rosa M, Fasano C, Panariello L, et al. Evidence for a recessive inheritance of Turcot's syndrome caused by compound heterozygous mutations within the PMS2 gene. Oncogene. 2000;19:1719-1723. (Pubitemid 30200974)
104. Thakker RV. Multiple endocrine neoplasia - syndromes of the twentieth century. J Clin Endocrinol Metabolism. 1998;83:2617-2620. (Pubitemid 28493749)
105. Lohmann DR, Brandt B, Hopping W, et al. The spectrum of RB1 germ-line mutations in hereditary retinoblastoma. Am J Human Genet. 1996;58:940-949. (Pubitemid 26115165)
106. Richter S, Vandezande K, Chen N, et al. Sensitive and efficient detection of RB1 gene mutations enhances care for families with retinoblastoma. Am J Human Genet. 2003;72:253-269. (Pubitemid 36194237)
107. Lance EI, DuPont BR, Holden KR. Expansion of the deletion 13q syndrome phenotype: a case report. J Child Neurol. 2007;22:1124-1127. (Pubitemid 47412688)
108. Meadows A. Trilateral retinoblastoma. Med Pediatric Oncol. 1986;14:323-326. (Pubitemid 17217050)
109. Kivela T. Trilateral retinoblastoma: ameta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. J Clin Oncol. 1999;17:1829-1837. (Pubitemid 29269254)
110. Abramson DH, Melson MR, Dunkel IJ, et al. Third (fourth and fifth) nonocular tumors in survivors of retinoblastoma. Ophthalmology. 2001;108:1868-1876. (Pubitemid 32905948)
111. Albert LS, Sober AJ, Rhodes AR. Cutaneous melanoma and bilateral retinoblastoma. J Am Acad Dermatol. 1990;23:1001-1004. (Pubitemid 20364354)
112. Abramson DH, Frank CM. Second nonocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk. Ophthalmology. 1998;105:573-579; discussion 9-80.
113. Dorfmuller G, Wurtz FG, Kleinert R, et al. Cerebral primitive neuro-ectodermal tumour following treatment of a unilateral retinoblastoma. Acta Neurochirurgica. 1997;139:749-755. (Pubitemid 27354722)
114. Traboulsi EI, Zimmerman LE, Manz HJ. Cutaneous malignant melanoma in survivors of heritable retinoblastoma. Arc Ophthalmol. 1988;106:1059-1061.
115. Belt PJ, Smithers M, Elston T. The triad of bilateral retinoblastoma, dysplastic naevus syndrome and multiple cutaneous malignant melanomas: a case report and review of the literature. Melanoma Res. 2002;12:179-182. (Pubitemid 34478460)
116. Kleinerman RA, Tucker MA, Abramson DH, et al. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst. 2007;99:24-31.
117. Wenzel CT, Halperin EC, Fisher SR. Second malignant neoplasms of the head and neck in survivors of retinoblastoma. Ear Nose Throat J. 2001;80:106, 9-12.
118. Kleinerman RA, Tarone RE, Abramson DH, et al. Hereditary retinoblastoma and risk of lung cancer. J Natl Cancer Inst. 2000;92:2037-2039. (Pubitemid 32045901)
119. Soloway HB. Radiation-induced neoplasms following curative therapy for retinoblastoma. Cancer. 1966;19:1984-1988.
120. Abramson DH, Ellsworth RM, Kitchin FD, et al. Second nonocular tumors in retinoblastoma survivors. Are they radiation-induced? Ophthalmology. 1984;91:1351-1355. (Pubitemid 15208903)
121. Kleinerman RA, Tucker MA, Tarone RE, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol. 2005;23:2272-2279. (Pubitemid 46218720)
122. Acquaviva A, Ciccolallo L, Rondelli R, et al. Mortality from second tumour among long-term survivors of retinoblastoma: a retrospective analysis of the Italian retinoblastoma registry. Oncogene. 2006;25:5350-5357. (Pubitemid 44299097)
123. Abramson DH, Ronner HJ, Ellsworth RM. Second tumors in nonirradiated bilateral retinoblastoma. Am J Ophthalmol. 1979;87:624-627. (Pubitemid 9141462)
124. Lueder GT, Judisch F, O'Gorman TW. Second nonocular tumors in survivors of heritable retinoblastoma. Arc Ophthalmol. 1986;104:372-373. (Pubitemid 16132996)
125. Derkinderen DJ, Koten JW, Wolterbeek R, et al. Non-ocular cancer in hereditary retinoblastoma survivors and relatives. Ophthalmic Paediatrics Genet. 1987;8:23-25. (Pubitemid 17035638)
126. Roarty JD, McLean IW, Zimmerman LE. Incidence of second neoplasms in patients with bilateral retinoblastoma. Ophthalmology. 1988;95:1583-1587.
127. Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst. 1993;85:1121-1128. (Pubitemid 23212278)
128. Moll AC, Imhof SM, Bouter LM, et al. Second primary tumors in patients with retinoblastoma. A review of the literature. Ophthalmic Genet. 1997;18:27-34. (Pubitemid 27222911)
129. Imhof SM, Moll AC, Hofman P, et al. Second primary tumours in hereditary- and nonhereditary retinoblastoma patients treated with megavoltage external beam irradiation. Documenta Ophthalmologica. 1997;93:337-344. (Pubitemid 28261028)
130. Kaye FJ, Harbour JW. For whom the bell tolls: susceptibility to common adult cancers in retinoblastoma survivors. J Natl Cancer Inst. 2004;96:342-343. (Pubitemid 38351289)
131. Fletcher O, Easton D, Anderson K, et al. Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst. 2004;96:357-363. (Pubitemid 38401013)
132. Mohney BG, Robertson DM, Schomberg PJ, et al. Second nonocular tumors in survivors of heritable retinoblastoma and prior radiation therapy. Am J Ophthalmol. 1998;126:269-277. (Pubitemid 28397100)
133. Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br J Cancer. 1986;53:661-671. (Pubitemid 16114627)
134. Markey MP, Bergseid J, Bosco EE, et al. Loss of the retinoblastoma tumor suppressor: differential action on transcriptional programs related to cell cycle control and immune function. Oncogene. 2007;26:6307-6318. (Pubitemid 47462102)
135. Sharma A, Comstock CE, Knudsen ES, et al. Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Cancer Res. 2007;67:6192-6203. (Pubitemid 47037500)
136. Agoston AT, Argani P, De Marzo AM, et al. Retinoblastoma pathway dysregulation causesDNAmethyltransferase 1 overexpression in cancer viaMAD2-mediated inhibition of the anaphase-promoting complex. Am J Pathol. 2007;170:1585-1593. (Pubitemid 47339303)
137. Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature. 1986;323:643-646. (Pubitemid 16008560)
138. Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst. 2001;93:618-629. (Pubitemid 32409629)
139. Strong LC, Herson J, Haas C, et al. Cancer mortality in relatives of retinoblastoma patients. J Natl Cancer Inst. 1984;73:303-311. (Pubitemid 14055209)
140. Sanders BM, Jay M, Draper GJ, et al. Non-ocular cancer in relatives of retinoblastoma patients. Br J Cancer. 1989;60:358-365. (Pubitemid 19227406)
141. Forrest AW. Tumors following radiation about the eye. Trans - Am Acad Ophthalmol Otolaryngol. 1961;65:694-717.
142. Meadows AT, Shields CL. Regarding chemoreduction for retinoblastoma and intracranial neoplasms. Arch Ophthalmol. 2004;122:1570-1571; author reply 1. (Pubitemid 39336571)
143. Blanquet V, Turleau C, Gross-Morand MS, et al. Spectrum of germline mutations in the RB1 gene: a study of 232 patients with hereditary and non hereditary retinoblastoma. Human Molecular Genet. 1995;4:383-388.
144. Bassal M, Mertens AC, Taylor L, et al. Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2006;24:476-483. (Pubitemid 46630467)